Key result
Inherited thrombophilia testing is not required outside clinical trials for women with recurrent pregnancy losses, as markers do not generally indicate a need for additional therapy during pregnancy.
Why the study?
Does inherited thrombophilia testing and antithrombotic therapy improve pregnancy outcomes in women with recurrent miscarriages or late pregnancy complications?
Does inherited thrombophilia testing and antithrombotic therapy improve pregnancy outcomes in women with recurrent miscarriages or late pregnancy complications?
Routine testing for inherited thrombophilia and subsequent antithrombotic therapy are not recommended for women with recurrent miscarriages or late pregnancy complications outside of clinical trials.
Recurrent miscarriages and pregnancy-related complications cause significant stress to couples looking for successful pregnancy outcome as well as to health care professionals. There is conflicting evidence with respect to the presence and the strength of associations between inherited thrombophilia and these complications. A complete thrombophilia screen is expensive, and no proven effective treatment for women with recurrent miscarriage and inherited thrombophilia is currently available. Based on the concept of microvascular thrombosis of the placenta, women with recurrent miscarriage and placenta-related complications frequently get treated with antithrombotic therapy. In this narrative review, the authors explore the evolving understanding and evidence of inherited thrombophilia in recurrent miscarriages and other pregnancy complications, and whether antithrombotic treatment would modify pregnancy outcome in women with inherited thrombophilia. Finally, they provide some personal recommendations based on available evidence for clinical practice. In summary, inherited thrombophilia testing is not required outside a clinical trial for women with recurrent pregnancy losses or late pregnancy complications. The presence of thrombophilia markers does not generally indicate additional therapy during pregnancy, even if a heritable thrombophilic defect is found in women with recurrent miscarriages or late pregnancy complications.
No takes yet. Share an insight, caveat, or question.
Deepa J. Arachchillage (2018) conducted a review in Recurrent miscarriages and pregnancy-related complications. Inherited thrombophilia testing was evaluated. Inherited thrombophilia testing is not required outside clinical trials for women with recurrent pregnancy losses, as markers do not generally indicate a need for additional therapy during pregnancy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: